unit: Paediatric Immunohaematology
gsd facility:Ospedale San Raffaele
Alessandro Aiuti is Deputy Director, Clinical Research Coordinator, Head of Unit onPathogenesis and Therapy of PID and Head of the Pediatric Clinical Research Unit of the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) in Milan; Director of the Pediatric Immunohaematology Unit, San Raffaele Research Hospital; Full Professor of Pediatrics at the Vita-Salute San Raffaele University; Director of the Residency Program of Pediatrics, Vita-Salute San Raffaele University.
He is M.D., specialized in Immunology and Ph.D. in Molecular and Cell Biology.
In 1998 he obtained the National Board in Haematology.
Since 1994 he has been working at the San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET), Milan, Italy, as Post Doctoral fellow (1994-1996), Group Leader (1997-2003), Head of Research Unit (2003-present), Clinical Research Coordinator (2009-present), Head of the Clinical Research Unit (2011-present), and as Deputy Director (2017-present).
From 2000 to 2007 he worked as M.D. Research Scientist for the San Raffaele Research Hospital, and from 2007 to 2014 as an Associate Professor of Paediatrics at the University of Rome Tor Vergata/Bambino Gesù Hospital, Rome, Italy. He received several awards, including Young Investigator Award (ASGCT) and ESGCT award for outstanding career and pioneering contributions to the field.
He is author to more than 150 peer reviewed publications (total citations of 9321, h-index Scopus 44).
He is a board member of the ESGCT since 2012, member of the Inborn Errors Working Party (IEWP) Studies Committee of the European Society for Bone and Marrow Transplantation (EBMT) (since 2015), member of ASGCT Hematologic and Immunologic Gene and Cell Therapy Committee (since 2016), and Co-Chair of the Stem Cell and Gene Therapy WP of European Reference Network (ERN) on Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases Network (RITA) (since 2017).
From 2013 to 05/2016 he was Chair of ASGCT Haematopoietic Cell Gene Therapy Committee, and from 2010 to 2012 he was member of Gene Therapy Working Party of European Medicines Agency (EMA).
In 2013 and 2017 he has been member of the Scientific Evaluation Committee (SEC) for E-Rare Joint Transnational Call European Commission.
His main interests are haematology, immunology and paediatrics, particularly in primary immunodeficiencies and gene therapy for Severe Combined Immunodeficiency due to the lack of Adenosine Deaminase (ADA-SCID) and Wiskott-Aldrich Syndrome.
His main domain of research are: Gene transfer into human HSC, gene therapy of PID and other genetic diseases (PI of 4 clinical trials: ADA-SCID, WAS, beta thalassemia and metachromatic leukodystrophy gene therapy), genetic and immunological characterization of PID in children, immune reconstitution after BMT and gene therapy.back to the search